Anti-helicobacter pylori properties of the ant-venom peptide bicarinalin

Belkhelfa, H.; Téné, N.; Guzman, J.; Haddioui-Hbabi, L.; Touchard, A.; Treilhou, M.; Castillo Pareja, Denis Helan; Sauvain, Michel Henri Auguste

dc.contributor.author	Guzman, J.
dc.contributor.author	Téné, N.
dc.contributor.author	Touchard, A.
dc.contributor.author	Castillo Pareja, Denis Helan
dc.contributor.author	Belkhelfa, H.
dc.contributor.author	Haddioui-Hbabi, L.
dc.contributor.author	Treilhou, M.
dc.contributor.author	Sauvain, Michel Henri Auguste
dc.date.accessioned	2018-11-30T23:41:31Z
dc.date.available	2018-11-30T23:41:31Z
dc.date.issued	2018
dc.identifier.uri	https://hdl.handle.net/20.500.12866/4218
dc.description.abstract	The venom peptide bicarinalin, previously isolated from the ant Tetramorium bicarinatum, is an antimicrobial agent with a broad spectrum of activity. In this study, we investigate the potential of bicarinalin as a novel agent against Helicobacter pylori, which causes several gastric diseases. First, the effects of synthetic bicarinalin have been tested against Helicobacter pylori: one ATCC strain, and forty-four isolated from stomach ulcer biopsies of Peruvian patients. Then the cytoxicity of bicarinalin on human gastric cells and murine peritoneal macrophages was measured using XTT and MTT assays, respectively. Finally, the preventive effect of bicarinalin was evaluated by scanning electron microscopy using an adherence assay of H. pylori on human gastric cells treated with bicarinalin. This peptide has a potent antibacterial activity at the same magnitude as four antibiotics currently used in therapies against H. pylori. Bicarinalin also inhibited adherence of H. pylori to gastric cells with an IC50 of 0.12 μg·mL–1 and had low toxicity for human cells. Scanning electron microscopy confirmed that bicarinalin can significantly decrease the density of H. pylori on gastric cells. We conclude that Bicarinalin is a promising compound for the development of a novel and effective anti-H. pylori agent for both curative and preventive use.	en_US
dc.language.iso	eng
dc.publisher	MDPI
dc.relation.ispartofseries	Toxins
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject	levofloxacin	en_US
dc.subject	human	en_US
dc.subject	Helicobacter pylori	en_US
dc.subject	Article	en_US
dc.subject	nonhuman	en_US
dc.subject	bacterial strain	en_US
dc.subject	unclassified drug	en_US
dc.subject	amoxicillin	en_US
dc.subject	animal cell	en_US
dc.subject	antibacterial activity	en_US
dc.subject	Antimicrobial peptide	en_US
dc.subject	Bacterial adhesion	en_US
dc.subject	bacterial growth	en_US
dc.subject	bicarinalin	en_US
dc.subject	Bicarinalin	en_US
dc.subject	CC50	en_US
dc.subject	clarithromycin	en_US
dc.subject	cytotoxicity	en_US
dc.subject	drug synthesis	en_US
dc.subject	Gastric cells	en_US
dc.subject	human cell	en_US
dc.subject	macrophage	en_US
dc.subject	metronidazole	en_US
dc.subject	minimum inhibitory concentration	en_US
dc.subject	mouse	en_US
dc.subject	MTT assay	en_US
dc.subject	scanning electron microscopy	en_US
dc.subject	selectivity index	en_US
dc.subject	SEM	en_US
dc.subject	venom	en_US
dc.subject	XTT assay	en_US
dc.subject	antimicrobial peptide	en_US
dc.subject	bacterial adhesion	en_US
dc.subject	gastric cells	en_US
dc.title	Anti-helicobacter pylori properties of the ant-venom peptide bicarinalin	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.3390/toxins10010021
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.01.07
dc.relation.issn	2072-6651